Dear Visitor,

Welcome to the Estracure, Inc website hosted on the corporate website of Duravest, Inc.

Estracure is developing a next-generation coronary stent that specifically addresses potential safety issues with the current generation of coronary drug-eluting stents and thus represents not just a potential niche player but a replacement product in this large market. The active agent in the Estracure stent -- 17-beta-estradiol -- has a pro-healing effect (by stimulating re-endothelialization) which has been documented by extensive in vitro and in vivo studies.

For questions and comments about the Estracure website or Estracure in general, please contact Mr. Peter Duffield who is the Administrative Director at Estracure (pduffield@capsnap.com).

About Duravest, Inc.
Duravest, Inc. (Other OTC: DUVT.PK) (XETRA: DUV.DE) is the global leader in the field of convergent medical technologies. The Duravest strategy encompasses three themes: (1) rapid commercialization of next-generation medical technologies by providing its subsidiaries with financial, operational and scientific support, (2) prioritization of safety and (3) development of convergent medical technologies that span the traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices.   Feel free to address questions about Duravest to info@duravestinc.com.

Estracure, Inc
Duravest, Inc